For the past eight decades, subcutaneous injection has been the main route used for supplementing the suboptimal insulin secretion for administering insulin as a treatment for diabetes mellitus. Although this method is effective, subcutaneous injections are painful, inconvenient and carry a high risk of infections leading to poor patient compliance. The insulin-encapsulated hepatitis E virus nanoparticle, composed of the noninfectious hepatitis E viral capsid, is expected to deliver insulin from the GI tract to the liver after ingestion. Hepatitis E virus nanoparticle could be the answer to the long search of effective and efficient means to administer insulin orally and the most preferred route of drug delivery with highest patient compliance.
Keywords: insulin drink; oral delivery; oral route administration.